Clay B Siegall
CIK 1167496 · President and CEO · last filed 2026-07-27
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SGEN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
BOTHELL, WA 98021
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMNM | President and CEO | 870,704 | $18.61 | $16.21M | $6.76M | 11 | 2026-07-27 |
| STTK | Director | 318,608 | $4.57 | $1.46M | $250.0K | 7 | 2026-06-11 |
| Tourmaline Bio, Inc. (TRML) Delisted | Director | — | $47.98 | — | $0 | 4 | 2025-10-28 |
| Seagen Inc. (SGEN) Delisted | President & CEO | 676,653 | $228.74 | $154.78M | -$229.11M | 168 | 2022-05-13 |
| NRIX | Director | — | $15.21 | — | $0 | 2 | 2022-05-06 |
| RARE | Director | 2,550 | $15.54 | $39.6K | -$2.97M | 9 | 2020-08-11 |
| ALDER BIOPHARMACEUTICALS INC (ALDR) Delisted | Director | 31,714 | — | — | -$1.44M | 7 | 2019-05-28 |
| SYNLOGIC, INC. (MIRN) Delisted | Director | — | — | — | $0 | 1 | 2016-09-06 |
Recent Filings · Page 2 of 22
211 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-07-16 | STTK | Grant (A) | — | $0 | EDGAR |
| 2025-06-06 | Tourmaline Bio, Inc. (TRML) Delisted | Grant (A) | — | $0 | EDGAR |
| 2025-03-26 | IMNM | Buy (P) | +137,100 | $999.5K | EDGAR |
| 2025-02-03 | IMNM | Buy (P) | +150,000 | $1.16M | EDGAR |
| 2024-11-25 | IMNM | Buy (P) | +100,000 | $962.2K | EDGAR |
| 2024-08-13 | IMNM | Grant (A) | — | $0 | EDGAR |
| 2024-06-21 | STTK | Grant (A) | — | $0 | EDGAR |
| 2024-06-07 | Tourmaline Bio, Inc. (TRML) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-05-21 | IMNM | Buy (P) | +100,000 | $1.39M | EDGAR |
| 2024-03-08 | STTK | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.